Endocr Metab Immune Disord Drug Targets
May 2024
Endocr Metab Immune Disord Drug Targets
November 2021
Aims: The aim of this study was to investigate the epidemiology of histology-proven Neuroendocrine neoplasms (NENs) in an Italian area.
Background: NENs are a rare and poorly known disease and the global incidence and prevalence appear to be increasing over the past decades.
Objective: The objectives of this study were to estimate the incidence and trends of NENs in a 250,000-inhabitant area in the North-East of Italy in the 1998-2018 period and to compare them with international data.
Background: Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control.
View Article and Find Full Text PDF